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ABSTRACT
Introduction: CORONARY is a large international
randomised controlled trial comparing coronary artery
bypass graft (CABG) surgery done with and without
a bypass pump. Compared with on-pump, off-pump
surgery may prevent acute kidney injury (AKI) in the
short term and may better preserve kidney function
1 year following surgery. Secondary analyses may also
clarify whether effects are similar in patients with and
without pre-operative chronic kidney disease and
whether AKI avoidance mediates preserved 1-year
kidney function.
Methods and analysis: With respect to the study
schedule, the last of 4752 patients from 79 sites in 19
countrieswererandomisedinNovember2011tocardiac
surgery performed with an on-pump or off-pump
procedure. The authors will use regression models to
comparethegroupsintheoutcomeofperi-operativeAKI
(percentchangeinserumcreatinine,$50%increasein
serum creatinine) and 1-year kidney function (per cent
change in estimated glomerular ﬁltration rate (eGFR),
$20% eGFR loss 1 year after surgery). The authors will
useinteractiontermsinregressionmodelstodetermine
ifthereisadifferentialimpactoftheinterventioninthose
with and without pre-existing chronic kidney disease.
The authors will use regression-based tests to
determine the proportion of the total effect of surgery
type (off-pump vs on-pump CABG) on 1-year eGFR
that is mediated by peri-operative AKI.
Ethics and dissemination: In the year 2009, the
authors were competitively awarded a grant from the
Canadian Institutes of Health Research to answer these
kidney questions in CORONARY. Ethics approval was
obtained for additional renal data collection in centres
that agreed to study participation (>90% of
participating centres). This collection began for
patients enrolled after 1 January 2010. Remaining
1-year renal outcome data will be collected throughout
2012. Results will be reported in 2013.
Clinical trial registration number: NCT 00463294. BACKGROUND
Coronary artery bypass grafting (CABG)
surgery is an effective way of improving
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ARTICLE SUMMARY
Article focus
- CORONARY is a large international randomised
controlled trial comparing coronary artery bypass
graft (CABG) surgery done with and without
a bypass pump.
- Compared with on-pump, off-pump surgery may
prevent AKI in the short term and may better
preserve kidney function 1 year after surgery.
- Secondary analyses may also clarify whether
effects are similar in patients with and without
pre-operative chronic kidney disease and
whether AKI avoidance mediates preserved
1-year kidney function.
Key messages
- Presented is this pre-speciﬁed CORONARY
kidney substudy analytic protocol.
- Data collection and analysis will be completed in
2013.
- Understanding the degree to which avoiding AKI
preserves longer term kidney function has
broader implications for the acceptability of
side effects and costs of interventions which
prevent AKI.
Strengths and limitations of this study
- This will be largest AKI prevention trial conducted
to date.
- It will be one of the ﬁrst trials to consider the
impact of a peri-operative intervention on longer
term kidney function.
- International recruitment across 19 countries will
provide generalisable estimates of the treatment
effect.
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Open Access Protocolsymptoms and prolonging life in patients with severe
coronary artery disease.
1 Globally, 1.25 million cardiac
surgeries are performed annually.
2 A frequent and
serious complication of CABG surgery is acute kidney
injury (AKI), which is a sudden deterioration in kidney
function. Peri-operative AKI is independently associated
with increased short- and long-term mortality, a greater
length of hospital stay and higher economic costs.
3
CABG surgery is usually performed with the use of
cardiopulmonary bypass (‘on-pump’). This requires
cannulation of the heart and aorta, cross clamping of the
ascending aorta and cardioplegic arrest. In this setting,
AKI is multifactorial: the bypass circuit changes blood
concentration and pulsatility and introduces a blood/
circuit interface, which stimulates a generalised inﬂam-
matory response including increased catecholamine
and free haemoglobin levels.
4 Furthermore, aorta
cannulation and cross clamping may lead to platelet or
atheromatous embolic phenomena.
CABG surgery performed on a beating heart without
the use of cardiopulmonary bypass (‘off-pump’) was
developed to avoid post-operative complications from
the pump. A systematic review published in 2010 evalu-
ated AKI across 22 randomised trials comparing
off-pump with on-pump surgery (total 4819 patients).
5
Off-pump CABG resulted in a 40% RR reduction in AKI
(variably deﬁned in the primary trials). The results did
not demonstrate statistical heterogeneity. However, as
concluded by the review authors, ‘different deﬁnitions of
AKI used in the individual trials and methodological
concerns preclude deﬁnitive conclusions about the
treatment effect’.
A limitation of most AKI prevention trials is a failure to
consider any sustained effect of the intervention on
longer term kidney function. It is possible that off-pump
compared with on-pump surgery better preserves 1-year
kidney function, but to our knowledge, this has not been
previously evaluated. This effect may be mediated
through the AKI itself (ie, avoiding AKI preserves kidney
function at 1 year
6 7) or may be mediated through other
pathways (ie, off-pump bypass improves cardiac function
which preserves 1-year kidney function). Understanding
the degree to which avoiding AKI preserves longer term
kidney function has broader implications for the
acceptability of side effects and costs of interventions
which prevent AKI. Finally, patients with pre-operative
chronic kidney disease (CKD) are at high risk of AKI and
are a subgroup where preservation of renal function is of
key interest.
8
CABG Off- or On-Pump Revascularisation Study
We are conducting the CABG Off- or On-Pump Revas-
cularisation Study (acronym CORONARY). The methods
of this large, international randomised controlled trial
are described elsewhere.
9 In brief, after obtaining written
informed consent, adult patients undergoing isolated
CABG surgery (with a median sternotomy) are allocated
to have the procedure done with or without a bypass
pump. Allocation is done by a voice-activated telephone
randomisation service. This trial is funded by the Cana-
dian Institutes of Health Research. With respect to the
study schedule, the last of 4752 patients from 79 sites in
19 countries were randomised in November 2011. The
primary 30-day composite outcome is total mortality,
stroke, non-fatal myocardial infarction or receipt of
dialysis for severe AKI. The 30-day results will be analysed
and reported in March 2012. One-year outcome data will
continue to be collected throughout 2012 and will be
reported in 2013.
In addition to the primary outcome, CORONARY is
uniquely positioned to answer important kidney-speciﬁc
questions. In the year 2009, we were competitively
awarded another grant from the Canadian Institutes of
Health Research to collect additional renal information
within CORONARY to address these questions. Ethics
approval was obtained for additional renal data collec-
tion in centres that agreed to study participation (>90%
of participating centres). This collection began for
patients enrolled after 1 January 2010. Remaining 1-year
renal outcome data will be collected throughout 2012.
Results will be reported in 2013.
The kidney questions detailed in the grant are
presented below and are followed by pre-speciﬁed
analytic plans.
Primary questions
1. In patients undergoing CABG surgery, does use of an
off-pump compared with an on-pump procedure (i)
reduce the risk of AKI during the hospital stay and (ii)
result in better kidney function 1 year after surgery?
Secondary questions
2. Does the presence of pre-operative CKD modify the
impact of surgery type (off-pump, on-pump) on kidney
outcomes?
3. If an off-pump compared with an on-pump procedure
results in better kidney function 1 year after surgery is
the effect mediated by avoiding peri-operative AKI?
CORONARY data collection
The pre-operative serum creatinine value (within 7 days
prior to randomisation) has been recorded since the start
of the trial, along with the peak value during the hospital
stay. We deﬁne pre-operative CKD as an estimated
glomerular ﬁltration rate (eGFR) <60 ml/min/1.73 m
2,
using the Chronic Kidney Disease Epidemiology Collab-
oration (CKD-EPI) equation (which requires knowledge
of whether a patient is of black race; <0.1% of CORO-
NARY patients).
10 In centres that agreed to additional
renal data collection, we started recording all serum
creatinine measurements during the hospital stay for
patients enrolled after 1 January 2010 (not just the peak
value) and a serum creatinine 1 year after surgery.
ANALYTIC PLAN
To reﬁne the analytic plan in December 2011, we
reviewed all CORONARY data without knowledge of
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CORONARY kidney substudy protocolpatient allocation. Table 1 presents AKI according to
modern staging systems.
11 12 Table 2 presents changes in
kidney function 1 year after surgery. The analytic plan
was ﬁnalised without any knowledge of CORONARY
outcomes by allocation group.
Patient selection
For CORONARY kidney substudy analyses, all rando-
mised patients will be included except as follows: (1)
patients receiving chronic haemodialysis prior to
randomisation (as these patients cannot develop AKIdto
date 1.3% of randomised patients), (2) patients with
a baseline eGFR <15 ml/min/1.73 m
2 prior to random-
isation (ie, patients with end-stage renal disease
(ESRD)
13; to date an additional 0.2% of patients), (3)
patients missing a pre-randomisation serum creatinine
value as we cannot reliably deﬁne AKI without knowledge
of the baseline value (<1% of patients) and (4) patients
who never undergo CABG surgery as they will not have
the opportunity to have any post-operative serum creati-
nine measurements (<1% of randomised patients).
Intervention group assignment
Patients are randomised to on-pump or off-pump CABG,
with randomisation stratiﬁed by centre. The intention-
to-treat principle will guide all analyses, irrespective of
whether there is a deviation from the randomly allocated
therapy. Currently, the cross-over rate is 4% from on-
pump to off-pump and 10% from off-pump to on-pump
surgery.
AKI during hospital stay
Peri-operative per cent change in serum creatinine
We will use a linear regression model to compare the
groups in the outcome of per cent change in serum
creatinine ((peak post-operative serum creatinined
pre-randomisation serum creatinine)/pre-random-
isation serum creatinine), stratiﬁed by centre and
adjusting for the following covariates: age (per year), sex,
left ventricular function categories ($50%, 35%e49%,
20%e34%, <20%), diabetes, pre-randomisation ACE
inhibitor or angiotensin receptor blocker use, pre-
randomisation statin use, pre-randomisation diuretic use,
urgent versus elective surgery and pre-randomisation
eGFR category (>60 ml/min/1.73 m
2, #60 ml/min/
1.73 m
2). We will include a missing data indicator value
for each covariate (at present, there is <1% missing for
each variable).
14 In patients who underwent surgery but
haveamissingpost-operative peakserumcreatininevalue
(<4% patients), we will carry the pre-randomisation
serum creatinine forward as the post-operative value
(which should provide a more conservative estimate of
the intervention effect than the alternative of removing
such patients). We will test model assumptions (detailed
in online appendix) and interpret a p value #0.05 as
statistically signiﬁcant. We will report the result as the
average difference in per cent change in serum creati-
nine between the surgical groups with 95% CI. Visually
the unadjusted results will be graphed as box-plots. A
sample of w4700 patients will have over 80% power to
detect a 5% or greater difference in the mean per cent
change in serum creatinine between the two groups
(a 0.05, independent samples t test; adequate power to
detect a small effect in relation to expected SD of 60).
Categorised AKI
We will use a logistic regression model to compare the
groups in the outcome of $50% increase in serum creat-
inine, stratiﬁed by centre and adjusting for previously
deﬁned covariates
11 15 16 We will test model assumptions
(detailed in online appendix) and will estimate the
adjusted RR of AKI with 95% CI (bootstrap method
Table 1 Per cent of CORONARY patients to date who met a deﬁnition of acute kidney injury according to modern staging
systems
All patients
(n[3089)
Patients with
a pre-operative
eGFR >60 ml/min/
1.73 m
2 (n[2372)
Patients with
a pre-operative
eGFR £60 ml/min/
1.73 m
2 (n[717)
Evidence of an absolute increase in SCr value $27 mmol/L
or an increase of $150% from the baseline SCr value
(AKIN stage 1 or more)
28.9% 25.3% 41.1%
Evidence of an increase in SCr value $150% ($1.5-fold)
from baseline (RIFLE risk category)
18.7% 17.0% 24.4%
Evidence of an increase in SCr value $200% ($twofold)
from baseline (RIFLE injury category, AKIN stage 2)
6.9% 5.6% 11.4%
Evidence of an increase in SCr value $300% ($threefold)
from baseline or a baseline SCr $354 mmol/l with an
increase $44 mmol/l from baseline. Any patient who
received acute dialysis is categorised in this category
(RIFLE failure category, AKIN stage 3)
2.2% 1.6% 4.2%
Receipt of acute dialysis 1.2% 0.6% 3.1%
Acute Kidney Injury Network (AKIN) and Risk, Injury, Failure, Loss and End-stage Renal Disease (RIFLE) classiﬁcation systems. The
categories are not mutually exclusive (ie, patients who meet the criteria for RIFLE injury also meet the criteria for RIFLE risk).
eGFR, estimated glomerular ﬁltration rate; SCr, serum creatinine.
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power to detect a 20% or more RR reduction should it
exist (two-tailed a 0.05, c
2 test). Of note, many factors
including haemodilution add ‘noise’ to post-operative
serum creatinine measurements. When the value is
markedlyelevated,weareconﬁdentthatthereasonisdue
to AKI. It is conceivable that an intervention effect will be
observed for categorised AKI but not per cent change in
creatinine. If the p value is greater for per cent change
than categorised AKI, we will interpret a p value #0.025
for categorised AKI as statistically signiﬁcant.
17 Because
categorised AKI is easy to interpret, if it meets criteria for
signiﬁcance, we will primarily focus on this outcome.
Supporting analyses
We will perform six analyses deﬁning AKI in other ways.
We will interpret a p value #0.05 as signiﬁcant provided
there is concordance with the primary results.
< Absolute change in serum creatinine from the
pre-randomisation value.
< $100% increase in serum creatinine (Risk, Injury,
Failure, Loss and End-stage Renal Disease (RIFLE)
injury category, AKIN (Acute Kidney Injury Network)
stage 2).
11 12
< $27 mmol/l or $50% increase in serum creatinine
(AKIN stage 1 or more).
12
< Composite of AKI or death during the hospital stay
(death rate w2% at 30 days; 90% of patients who die
have post-operative serum creatinine recorded; death
rate within 2 days of surgery is <0.5%).
< Evidence of a rise in serum creatinine in ﬁrst 48 h after
surgery (for patients enrolled after 1 January 2010).
18
< AKI that also considers later post-operative rises in
serum creatinine in relation to earlier post-operative
measurements (supplements the primary analysis
which only considers peak post-operative measure-
ment during hospital stay in relation to pre-random-
isation value).
18
Kidney function 1 year after surgery
One-year per cent change in eGFR
Similar to the previously described AKI analysis, we will
use a linear regression model to compare the groups in
the outcome of per cent change in eGFR 1 year after
surgery ((post-operative eGFR measured 1 year after
surgerydpre-randomisation eGFR)/pre-randomisation
eGFR), stratiﬁed by centre and adjusting for covariates
described for AKI. In patients with missing 1-year values
(w5% for reasons of death, target <10% for reasons of
missing data), we will substitute the pre-randomisation
eGFR value. We will impute an eGFR value of 5 ml/min/
1.73 m
2 for any patient who developed ESRD anytime in
follow-up (<0.1%) or who died after receiving acute
dialysis (w0.6% patients). With at least 1800 patients, we
will have over 80% power to detect a difference of 4% or
more between the two surgical groups (a 0.05, inde-
pendent samples t test, adequate power to detect a small
to moderate effect in relation to expected SD of 25).
Categorised change in kidney function
Similar to the previously described AKI analysis, we will
use a logistic regression model to compare the groups
on the outcome of $20% eGFR decrease 1 year after
surgery (ie, loss of over a ﬁfth of kidney function).
Anyone who develops ESRD in follow-up, or receives
acute dialysis and dies before a serum creatinine
measurement can be obtained, will be counted as having
met this deﬁnition. We will have between 75% and 89%
power to detect a 25%e30% RR reduction should it exist
(two-tailed a 0.05, c
2 test). As with AKI, it is conceivable
that an intervention effect will be observed in the cate-
gorised but not continuous outcome. In this scenario, we
will interpret statistical signiﬁcance as described for AKI.
Supporting analyses
We will perform two analyses examining 1-year kidney
function in other ways. We will interpret a p value #0.05
as signiﬁcant provided there is concordance with the
primary results.
< Absolute change in serum creatinine from the
pre-randomisation value.
< Rank-based assessment accounting for potential
competing event of death (detailed in online
appendix).
Subgroup analyses: presence of pre-operative CKD
We will use interaction terms in the previously described
linear and logistic regression models to determine if
Table 2 One-year change in eGFR compared with the pre-operative value, expressed as categories
All patients
(n[1241)
Patients with a pre-operative
eGFR >60 ml/min/
1.73 m
2 (n[910)
Patients with a pre-operative
eGFR £60 ml/min/
1.73 m
2 (n[331)
$15% reduction in eGFR 23% 24% 21%
$20% reduction in eGFR 18% 19% 15%
$25% reduction in eGFR 12% 12% 11%
$50% reduction in eGFR 3% 2% 5%
$5 ml/min/1.73 m
2 reduction in eGFR 38% 43% 24%
$10 ml/min/1.73 m
2 reduction in eGFR 25% 29% 15%
Anyone who developed end-stage renal disease in follow-up was counted as meeting the reduction in eGFR deﬁnition as was anyone who
received acute dialysis who subsequently died before their 1-year serum creatinine measurement.
eGFR, estimated glomerular ﬁltration rate using the Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) equation.
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with and without CKD. We will interpret a p value #0.05
as statistically signiﬁcant. Despite the size of CORO-
NARY, there will only be adequate statistical power for
very large subgroup effects.
Mediation analysis: impact of AKI on longer term kidney
function
A mediating variable is one that explains all or part of
the association between a predictor and a response.
19 In
CORONARY, mediation will occur if on-pump versus off-
pump CABG surgery inﬂuences the development of AKI,
which inﬂuences 1-year kidney function.
20 Regression-
based tests for mediation have been well developed and
are widely used.
21 22 Figure 1 presents our analytic
framework. We will test for a signiﬁcant mediation effect
(methods detailed in online appendix). We will report
the proportion of the total effect of surgery type (off-
pump vs on-pump CABG) on per cent change in 1-year
eGFR that is mediated by peri-operative per cent change
in serum creatinine. As well, we will consider mediation
with AKI deﬁned as a categorical variable (methods
detailed in online appendix).
CONCLUSIONS
The sample in CORONARY almost exceeds the
combined number of patients enrolled across 70 rand-
omised controlled trials, which tested strategies to
prevent or treat AKI in cardiac surgery.
23 It will be the
largest AKI prevention trial conducted to date. Interna-
tional recruitment across 19 countries will provide
generalisable estimates of the treatment effect. In this
report, we have judiciously pre-speciﬁed the main ques-
tions and analytic protocol that will be used to test
relevant kidney hypotheses in CORONARY. We have
done so to minimise the chance of spurious post-hoc
assertions of effect, so that the kidney results from this
large international trial are robust and believable.
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